Hypertension:抗高血压药物服用者与非服用者之间的血压相关风险比较!

2018-04-26 xing.T MedSci原创

总之,这项基于人群的研究表明血压与不良结局之间的相关性在积极服用抗高血压药物的受试者中呈J形,但在未服用者或不规则服药的受试者中是线性或平坦的,然后增加。

很少有研究比较抗高血压药物服用者和未服用者之间血压(BP)相关的结局。近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员从全国健康保险服务健康筛查数据库中构建了一个以人群为基础的队列,该队列包含了年龄在40至79岁之间的492540名韩国人,这些受试者既往无心肌病。

该研究的主要的综合结局为心源性死亡(或入住重症监护病房)、因心肌梗死卒中的血运重建以及新发的终末期肾脏疾病。研究人员使用随时间变化的COX模型,随访期间每年根据BP和抗高血压的使用情况来估计风险比。

在为期超过10年的随访中,发生主要结局的受试者为26122名,以及33550人死亡。在未服用抗高血压药物的受试者中,主要结局的风险从105/65mmHg的血压线性增加,而全因死亡率的风险从115/75mmHg开始增加。在不规则服药的受试者中,随着BP增加>115/75mmHg,主要结局的风险增加。在积极服药的受试者中,收缩压<115mmHg和>135mmHg、舒张压<65mmHg和>85mmHg会导致主要结局的风险增加,收缩压<125mmHg和>135mmHg或145mmHg会导致全因死亡率风险增加。

总之,这项基于人群的研究表明血压与不良结局之间的相关性在积极服用抗高血压药物的受试者中呈J形,但在未服用者或不规则服药的受试者中是线性或平坦的,然后增加。

原始出处:

Hae Hyuk Jung,et al. Blood Pressure–Related Risk Among Users Versus Nonusers of Antihypertensives A Population-Based Cohort in Korea.Hypertension.2018. https://doi.org/10.1161/HYPERTENSIONAHA.118.11068

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2019-02-09 feather89
  6. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-05-01 yfjms

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2038890, encodeId=ba332038890cc, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Thu Dec 06 11:56:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078454, encodeId=3d4620e845416, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sun Jun 03 07:56:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811925, encodeId=6f5b18119258c, content=<a href='/topic/show?id=002288962aa' target=_blank style='color:#2F92EE;'>#血压相关风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88962, encryptionId=002288962aa, topicName=血压相关风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Mon Apr 30 16:56:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027113, encodeId=e3f0202e11399, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Dec 23 22:56:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727260, encodeId=53b31e272605b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 09 04:56:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039783, encodeId=40a42039e83df, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue Jan 15 18:56:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310915, encodeId=0d39310915a5, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 01 08:09:43 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501283, encodeId=bf4b150128344, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545681, encodeId=a7011545681c6, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Sat Apr 28 13:56:00 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=309840, encodeId=e7ee30984072, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Fri Apr 27 17:22:38 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 yfjms

    学习

    0

相关资讯

Hypertension:抗高血压药物能延缓青光眼的发生

尽管高血压,通过服用抗高血压药物治疗来确定,与青光眼之间存在正相关性,但是该研究的结果表明,抗高血压药物本身可能对青光眼的发生发展具有预防作用。

CMAJ:α-受体阻滞剂和缺血性卒中,你知多少?

背景:在早期治疗阶段,α-受体阻滞剂因其急性低血压效应而臭名昭著。因为,急性脑低血压可能引起缺血性卒中,研究者应用自控病例系列设计探索应用α-受体阻滞剂早期,发生缺血性卒中的风险。方法:研究者识别台湾全民健康保险索赔数据库中2007年开始应用α-受体阻滞剂的50医生的男性,并且在2007-2009年诊断为缺血性卒中的患者。患者开始应用α-受体阻滞剂的第一天,记录为指数日期。研究者根据与指数日期的关

J Hypertens:宫内暴露于抗高血压药物与新生儿和儿童健康结局的相关性分析!

目前这项系统评价的结果表明缺乏相关的已发表的高质量研究。少数研究表明可能增加儿童不良健康结局的风险;然而,大多数已发表的研究都存在方法论上的缺点和/或缺乏统计效能,因此,无法得出任何确切的结论。

Hypertension:孕妇使用抗高血压药物和子代先天性心脏病有啥关系?

该研究结果支持和扩展了早期NBDPS的研究结果,即抗高血压药物使用可能与特异性CHD的风险增加有关,尽管我们不能完全排除潜在疾病特征的混杂影响。

Obstet Gynecol:分娩住院期间并发先兆子痫孕妇使用抗高血压药物治疗分析!

由此可见,使用多种抗高血压药物治疗先兆子痫的比例在轻度、中度和严重先兆子痫患者中有所增加。使用抗高血压药物不同医院差异很大,这一趋势与母亲卒中风险降低有关。

Neurology:出院时抗高血压药物处方会影响卒中患者生存!

由此可见,在卒中或TIA出院后接受抗高血压药物治疗的患者比没有使用这些药物的患者具有更好的心血管和全因死亡结局。